Drug Repurposing: From AI to Evidence
ZaTxGNN uses the Harvard TxGNN model to predict drug repurposing candidates for 455 SAHPRA-approved drugs, identifying potential new therapeutic uses.
Browse Drug Reports Learn Methodology
Drug Search
Enter a drug name or disease name to find repurposing predictions. Supports generic names, brand names, and disease keywords.
Key Features
Each report integrates clinical trial IDs (NCT), literature references (PMID), and SAHPRA approval information for complete traceability.
L1 (Multiple Phase 3 RCTs) to L5 (AI prediction only) classification helps prioritize candidates for validation.
Focused on 455 SAHPRA-approved medicines with repurposing predictions ready for research.
FHIR R4 compliant API and SMART on FHIR app for seamless EHR integration.
Quick Navigation
| Category | Description | Link |
|---|---|---|
| High Evidence | L1-L2, priority for clinical evaluation | View drugs |
| Medium Evidence | L3-L4, requires additional validation | View drugs |
| AI Predictions | L5, research direction reference | View drugs |
| Full Drug List | All 455 drugs (searchable) | Drug List |
| Health News | Automated health news monitoring | View News |
| FHIR API | Integration endpoints | FHIR Metadata |
About This Project
ZaTxGNN uses the TxGNN deep learning model published by Harvard’s Zitnik Lab in Nature Medicine to predict potential new therapeutic uses for SAHPRA-approved medications.
“TxGNN is the first foundation model designed for clinician-centered drug repurposing, integrating knowledge graphs with deep learning to predict drug efficacy for rare diseases.” — Huang et al., Nature Medicine (2023)
Statistics
| Item | Count |
|---|---|
| Drug Reports | 455 |
| Regulatory Agency | South African Health Products Regulatory Authority (SAHPRA) |
Data Sources
This report is for research purposes only and does not constitute medical advice. Drug use should follow physician guidance. Any drug repurposing decisions require complete clinical validation and regulatory review.
Last updated: 2026-03-10 | Maintainer: 藥提醒科技有限公司 (yao.care)
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).
ZaTxGNN is the South Africa site of the company’s “TxGNN Drug Repurposing” product line.
The same system is deployed across 30 countries and regions, each named {CC}TxGNN
(JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care.
Product overview: https://www.yao.care/medical/txgnn/.
The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.